TSLA:NASDAQTesla, Inc. Analysis
Data as of 2026-07-10 - not real-time
$408.96
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Tesla’s stock is trading at $408.96, sitting just above the 20‑day SMA of 400.94 but below both the 50‑day (409.22) and 200‑day (418.15) averages, confirming a short‑term bearish bias despite a bullish MACD histogram (+1.27) and a neutral RSI of 51.6. The shares have rallied on a surprise Q2 delivery beat of 480,126 units – a 25% year‑over‑year jump that lifted sentiment to “Extreme Greed” (Fear/Greed Index 94.13) and pushed the volume trend to stable levels. However, volatility remains elevated at 58.8% over the past 30 days and the beta of >2 underscores heightened market sensitivity, while the price is perched near the technical resistance of 432.86 and well above the support of 368.60.
Fundamentally, Tesla posts solid top‑line growth of 15.8% YoY on $97.9 B revenue, yet margins are thin (gross 19%, operating 4.2%) and cash conversion modest (free cash flow $5.25 B). The balance sheet shows abundant cash ($44.7 B) but a high debt‑to‑equity ratio of 18.7, and valuation metrics are extreme – a trailing PE of 371.8 and forward PE of 158.7 dwarf the DCF‑derived fair value of $42.7, leaving only a modest analyst upside of 3.8%. While the consensus remains a “Buy” with median price target $455, the combination of lofty multiples, high volatility, and regulatory headwinds suggests caution, positioning the stock as overvalued on current fundamentals but still buoyed by growth narratives around AI, FSD subscriptions, and robotaxi expansion.
Fundamentally, Tesla posts solid top‑line growth of 15.8% YoY on $97.9 B revenue, yet margins are thin (gross 19%, operating 4.2%) and cash conversion modest (free cash flow $5.25 B). The balance sheet shows abundant cash ($44.7 B) but a high debt‑to‑equity ratio of 18.7, and valuation metrics are extreme – a trailing PE of 371.8 and forward PE of 158.7 dwarf the DCF‑derived fair value of $42.7, leaving only a modest analyst upside of 3.8%. While the consensus remains a “Buy” with median price target $455, the combination of lofty multiples, high volatility, and regulatory headwinds suggests caution, positioning the stock as overvalued on current fundamentals but still buoyed by growth narratives around AI, FSD subscriptions, and robotaxi expansion.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent delivery beat exceeds expectations
- Bullish MACD histogram despite bearish trend
- Price approaching technical resistance
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Analyst median price target of $455 implies upside
- Growing recurring revenue from FSD and robotaxi initiatives
- Strong cash position offsetting high debt levels
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic shift toward AI and robotics platform
- Potential long‑term revenue from autonomous services
- Robust revenue growth and expanding global footprint
Key Metrics & Analysis
Financial Health
Revenue Growth15.80%
Profit Margin3.95%
P/E Ratio371.8
ROE4.90%
ROA2.23%
Debt/Equity18.74
P/B Ratio18.7
Op. Cash Flow$16.5B
Free Cash Flow$5.3B
Technical Analysis
TrendBearish
RSI51.6
Support$368.60
Resistance$432.86
MA 20$400.94
MA 50$409.22
MA 200$418.15
MACDBullish
VolumeStable
Fear & Greed Index94.13
Valuation
Fair Value$42.75
Target Price$424.56
Upside/Downside3.81%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.13
Volatility58.77%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.